Navigation Links
Cempra, Inc. Reports Fourth Quarter and Full Year 2012 Financial and Operating Results
Date:2/28/2013

CHAPEL HILL, N.C., Feb. 28, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the fourth quarter and full year ended Dec. 31, 2012. The company will host a conference call and webcast at 4:30 p.m. EST, today.

"2012 was a transformational year for Cempra," said Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra. "We raised sufficient capital through our IPO and a subsequent private placement to advance our two differentiated antibiotics in clinical development.  Solithromycin is now in the first of two planned Phase 3 clinical trials in community-acquired bacterial pneumonia or CABP and Taksta (CEM-102) is undergoing a Phase 2 trial in patients with prosthetic joint infections or PJIs.  2013 will also be an important year as we expect to hold an end-of-Phase 2 meeting with the FDA during the first half of 2013 for solithromycin in CABP as the key step in preparing for the IV-to-oral second Phase 3 trial, which we expect to start in the second half of 2013 subject to available resources.  We also anticipate presenting some top-line results for the TAKSTA™ Phase 2 trial in PJIs in the fourth quarter of 2013."

Financial ResultsQuarter ended December 31, 2012 compared to quarter ended December 31, 2011

For the quarter ended December 31, 2012, Cempra reported a net loss of $6.6 million, or $0.26 per share, compared to a net loss of $3.8 million, or $7.13 per share, for the same period in 2011. 

Research and development expense in the quarter ended December 31, 2012, was $4.4 million, a 20
'/>"/>

SOURCE Cempra, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. United States Patent and Trademark Office to Require Signed NDA Affects Many Reports Wysebridge
2. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2013
3. Soligenix Reports Year-End 2012 Financial Results and Highlights Recent Accomplishments
4. InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
5. Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
6. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
7. Neuland Labs Reports Third Quarter Fiscal Year 2013 Financial Results
8. Intraocular Lens (IOL) Market Worth $3.8 Billion By 2018 Say New Research Report at ReportsnReports.com
9. Regenerative Medicine and Stem Cells Market Deals Analysis in New Research Report at ReportsnReports.com
10. Cellular Therapy Market and Cord Blood Market 2013 Industry Research Report: MarketResearchReports.Biz
11. Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... , October 27, 2014 ... right to produce, exhibit and sell its artificial ... to impeach their patent.      (Photo: ... four years of fighting, the definitive judgement has ... and produces innovative and accessible hi-tech prostheses with ...
(Date:10/27/2014)... The “Molecular Diagnostic Market by Application ... DNA Sequencing), End User (Hospital, Laboratories), & by ... to 2018” provides a detailed overview of the ... and strategies impacting the global molecular diagnostics market ... revenue and share analysis. , The global molecular ...
(Date:10/27/2014)... 27, 2014 The report “Smart ... Traffic Management, Communication, Monitoring), and by Display (Variable ... 2019” segments the global market into various sub-segments ... also identifies the drivers and restraints for this ... , Browse 75 market tables and 37 figures ...
(Date:10/27/2014)... October 27, 2014 Investor-Edge has ... (NASDAQ: NBIX ), Insmed Inc. (NASDAQ: ... BCRX ), Dyax Corporation (NASDAQ: DYAX ), ... five companies can be accessed at: http://investor-edge.com/register ... Composite ended at 4,483.72, up 0.69%, the Dow Jones ...
Breaking Biology Technology:Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 5Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 2Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 3Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5
... NBIX ) today announced its financial results for the ... the fourth quarter of 2010, the Company reported net income of ... loss of $7.9 million, or $0.20 per basic share, for the ... the Company reported a net loss of $8.0 million, or $0.15 ...
... Technologies, Inc., a privately-held orthobiologics company, announced today that ... is scheduled to present at Canaccord Genuity,s Musculoskeletal Conference ... February 15, 2011 at 10:00 AM (PT).  The conference, ... Meeting, will feature presentations from over 60 public and ...
... Mass., Feb. 10, 2011 Qteros, Inc., ... Bioprocessing (CBP) platform for the lowest-cost production ... engagements across the United States and Europe for members ... Qteros, Senior Vice President, Commercial Development and Engineering, will ...
Cached Biology Technology:Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 2Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 3Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 4Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 5Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 6Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results 7ISTO Technologies, Inc. to Present at Canaccord Genuity's Musculoskeletal Conference 2Qteros Management to Present at Notable Alternative Energy Conferences in February 2
(Date:10/29/2014)... At a ceremony held in New York City on ... King, the American Cancer Society Professor of Genome Sciences ... and 2008 Honorary Doctor of Philosophy of Tel Aviv ... in Medical Science. , In addition to her honorary ... Lecturer at the TAU School of Medicine, and for ...
(Date:10/29/2014)... Hebei, China — BGI Tech and Hebei Agricultural University ... Jujube genome. Jujube is the most economically important member ... particularly difficult to sequence due the high level of ... time that a genome in the Rhamnaceae (Buckthorn) family ... in Nature Communications . , Jujube ...
(Date:10/28/2014)... the tragic realities of cancer is that the ... and their effectiveness varies unpredictably from patient to ... to change this reality by rapidly assessing how ... individual,s cancer before chemotherapy begins. , A team ... Assistant Professor Melissa Skala has developed the technique, ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree 2Improving breast cancer chemo by testing patient's tumors in a dish 2Improving breast cancer chemo by testing patient's tumors in a dish 3
... A new computer model of the Gulf of Mexico ... how underwater currents may have primed marine microorganisms to degrade ... of water move over the ruptured well, picking up hydrocarbons. ... over the well, the bacteria have already been activated, are ...
... Species pairs that disappear through hybridization after ... the disturbance is removed, according to a new ... reemergence might happen. The findings, published in ... conservationists and ecosystem managers interested in preserving, or ...
... Foundation for Biodiversity, the Charter Provincial Council of Gipuzkoa and ... be studying the re-stocking of the three eel phases (elver, ... and July, respectively, in three streams of the Oria basin. ... be able to manage the species and thus contribute to ...
Cached Biology News:Gulf currents primed bacteria to degrade oil spill 2Species reemergence after collapse: Possible but different 2A study will enable the survival and growth of the 3 development phases of the European eel 2
... The ProteoExtract™ Protein Precipitation Kit ... up of proteins from aqueous samples. ... by the presence of non-protein impurities ... in the protein sample that interfere ...
... activated carrier proteins to simplify the ... Activated Carrier Proteins are commonly used ... a heterobifunctional cross-linker (Sulfo-SMCC). This activation ... protein. Thus allowing the maleimide-activated ...
... This kit allows for rapid, convenient, ... The simple bind/wash/elute process utilizes a spin ... uses beads for concentration of proteins which ... beads are strong ion exchangers, offering high ...
... optically clear polystyrene with frosted labeling ... for cell counting. 100% integrity tested. ... new product number, created to easily ... no availability yet, please order under ...
Biology Products: